Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human IL6ST Antibodies:
anti-Mouse (Murine) IL6ST Antibodies:
anti-Rat (Rattus) IL6ST Antibodies:
Go to our pre-filtered search.
Human Monoclonal IL6ST Primary Antibody for FACS, IP - ABIN1383683
Wijdenes, Heinrich, Müller-Newen, Roche, Gu, Clément, Klein: Interleukin-6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies. in European journal of immunology 1996
Show all 26 Pubmed References
Human Monoclonal IL6ST Primary Antibody for FACS, IP - ABIN1383685
Fourcin, Chevalier, Guillet, Robledo, Froger, Pouplard-Barthelaix, Gascan: gp130 transducing receptor cross-linking is sufficient to induce interleukin-6 type responses. in The Journal of biological chemistry 1996
Show all 24 Pubmed References
Human Monoclonal IL6ST Primary Antibody for FACS - ABIN1383678
Gu, Wijdenes, Zhang, Hallet, Clement, Klein: Anti-gp130 transducer monoclonal antibodies specifically inhibiting ciliary neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory factor or oncostatin M. in Journal of immunological methods 1996
Show all 19 Pubmed References
Human Monoclonal IL6ST Primary Antibody for FACS - ABIN1383682
Chevalier, Fourcin, Robledo, Wijdenes, Pouplard-Barthelaix, Gascan: Interleukin-6 family of cytokines induced activation of different functional sites expressed by gp130 transducing protein. in The Journal of biological chemistry 1996
Show all 15 Pubmed References
Human Monoclonal IL6ST Primary Antibody for FACS - ABIN1383681
Auguste, Guillet, Fourcin, Olivier, Veziers, Pouplard-Barthelaix, Gascan: Signaling of type II oncostatin M receptor. in The Journal of biological chemistry 1997
Show all 5 Pubmed References
Mouse (Murine) Monoclonal IL6ST Primary Antibody for FACS - ABIN4896626
Pratama, Srivastava, Williams, Papa, Lee, Dinh, Hutloff, Jordan, Zhao, Casellas, Athanasopoulos, Vinuesa: MicroRNA-146a regulates ICOS-ICOSL signalling to limit accumulation of T follicular helper cells and germinal centres. in Nature communications 2015
Show all 4 Pubmed References
Mouse (Murine) Monoclonal IL6ST Primary Antibody for FACS - ABIN4896627
Nagashima, Okuyama, Hayashi, Ishii, So: TNFR-Associated Factors 2 and 5 Differentially Regulate the Instructive IL-6 Receptor Signaling Required for Th17 Development. in Journal of immunology (Baltimore, Md. : 1950) 2016
Show all 4 Pubmed References
Human Monoclonal IL6ST Primary Antibody for FACS - ABIN1383684
Müller-Newen, Köhne, Keul, Hemmann, Müller-Esterl, Wijdenes, Brakenhoff, Hart, Heinrich: Purification and characterization of the soluble interleukin-6 receptor from human plasma and identification of an isoform generated through alternative splicing. in European journal of biochemistry / FEBS 1996
Show all 4 Pubmed References
Human Monoclonal IL6ST Primary Antibody for FACS - ABIN4897911
Larsen, Hansen, Møller, Madsen, Scheller, Nielsen, Petersen: Sortilin facilitates signaling of ciliary neurotrophic factor and related helical type 1 cytokines targeting the gp130/leukemia inhibitory factor receptor beta heterodimer. in Molecular and cellular biology 2010
Show all 3 Pubmed References
Human Monoclonal IL6ST Primary Antibody for FACS - ABIN4897910
Cocco, Di Carlo, Zupo, Canale, Zorzoli, Ribatti, Morandi, Ognio, Airoldi: Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo. in Leukemia 2012
Show all 3 Pubmed References
an impaired oxidative stress response in hepatocytes with gp130 gain-of-function mutations, as detected in dysplastic intrahepatic nodules and hepatocellular adenomas, is one of the central oncogenic mechanisms in chronic liver inflammation.
The sgp130, IL-6 (show IL6 Antibodies), and sIL (show PMEL Antibodies)-6R concentrations were statistically significantly elevated in patients with diabetic retinopathy (DR), suggesting a probable contributing role of the IL-6 (show IL6 Antibodies) trans-signaling pathway to the pathophysiology of DR.
This functional mouse model of PMM2-CDG, in vitro assays and identification of the novel gp130 biomarker all shed light on the human disease, and moreover, provide the essential tools to test potential therapeutics for this untreatable disease.
we developed a CRISPR-Cas9-based tool for specific DNA methylation (show HELLS Antibodies) consisting of deactivated Cas9 (dCas9) nuclease (show DCLRE1C Antibodies) and catalytic domain of the DNA methyltransferase (show DNMT1 Antibodies) DNMT3A (show DNMT3A Antibodies) targeted by co-expression of a guide RNA to any 20 bp DNA sequence followed by the NGG trinucleotide.we demonstrated that directed DNA methylation (show HELLS Antibodies) of a wider promoter region of the target loci IL6ST and BACH2 (show BACH2 Antibodies) decreased their expression
data suggest that the different sgp130 forms are released from cells into their immediate surroundings and appear to form cell-associated gradients to modulate their own susceptibility for IL-6 (show IL6 Antibodies) trans-signaling.
Data indicate possible associations between pretransplant levels of CRP (show CRP Antibodies)/IL-6 /IL-6 (show IL6 Antibodies) receptor /gp130 and posttransplant outcomes.
Soluble glycoprotein 130 and hsp27 (show HSPB1 Antibodies) are novel candidate biomarkers for diagnosing Chronic Heart Failure with preserved ejection fraction and thus warrant further investigation; neither dpp4 (show DPP4 Antibodies) nor CTSS (show CTSS Antibodies) showed promise as biomarkers of Chronic Heart Failure.
Intracellular p19 (show CDKN2D Antibodies) associated with the cytokine receptor (show EBI3 Antibodies) subunit gp130 and stimulated the gp130-dependent activation of signal transducer and activator of transcription 3 (STAT3 (show STAT3 Antibodies)) signaling
High serum GP130 levels were associated with Chronic Spontaneous Urticaria.
PECs exhibited higher proliferation in response to IL-6 (show IL6 Antibodies)/sIL (show PMEL Antibodies)-6R co-treatment compared with TECs in HCC (show FAM126A Antibodies) via the up-regulation of gp130 /JAK2 (show JAK2 Antibodies)/STAT3 (show STAT3 Antibodies).
EBI3 can mediate IL-6 trans-signaling in a process that involves gp130
Blocking IL-6 (show IL6 Antibodies) trans-signaling in the CNS abrogates the ability of IL-6 (show IL6 Antibodies) to suppress feeding. Furthermore, gp130 (show LRPPRC Antibodies) expression is enhanced in the paraventricular nucleus of the hypothalamus (PVH) of obese mice, and deletion of gp130 (show LRPPRC Antibodies) in the PVH attenuates the beneficial central IL-6 (show IL6 Antibodies) effects on metabolism
C2C12 myotubes possesses a mechanism for regulating IL-6R and gp130 expression following lipoic acid treatment or heat shock.
Results suggest that the protective role of gp130 (show LRPPRC Antibodies)-dependent STAT3 (show STAT3 Antibodies) activation in experimental colitis involves the expansion and activation of mucosal myeloid-derived suppressor cells.
IL-6/gp130 signalling in the osteoclast is not essential for normal bone resorption in vivo, but maintains both trabecular and periosteal bone formation in male mice by promoting osteoblast activity through the stimulation of osteoclast-derived coupling factors and osteotransmitters
gp130 (show LRPPRC Antibodies)-mediated adipose tissue lipolysis promotes hepatic steatosis and insulin (show INS Antibodies) resistance.
differences exist in the expression of receptors utilized by the IL-6 (show IL6 Antibodies)/gp130 (show LRPPRC Antibodies) family of cytokines in astrocytes and microglia, and (2) the findings provide a molecular basis for the differential response to oncostatin M (show OSM Antibodies) by astrocytes versus microglia
Deregulation of gp130 (show LRPPRC Antibodies)/STAT3 (show STAT3 Antibodies) signalling augments the acute phase reponse and macrophage infiltration during atherosclerosis without impacting on the development of aortic plaques.
The expression of IL-6, IL-6R and gp130 transcripts were detected very early, increased during the first week of life and were predominantly expressed in the head, epidermis and neuromasts of the anterior and posterior lateral line system.
IL-6sR and gp130 (show ANPEP Antibodies), but not IL-6R alpha (show IL6R Antibodies), play important roles in regulation of granulosa cell survival
The protein encoded by this gene is a signal transducer shared by many cytokines, including interleukin 6 (IL6), ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), and oncostatin M (OSM). This protein functions as a part of the cytokine receptor complex. The activation of this protein is dependent upon the binding of cytokines to their receptors. vIL6, a protein related to IL6 and encoded by the Kaposi sarcoma-associated herpesvirus, can bypass the interleukin 6 receptor (IL6R) and directly activate this protein. Knockout studies in mice suggest that this gene plays a critical role in regulating myocyte apoptosis. Alternatively spliced transcript variants encoding distinct isoforms have been described. A related pseudogene has been identified on chromosome 17.
, IL-6 receptor subunit beta
, IL-6R subunit beta
, gp130 of the rheumatoid arthritis antigenic peptide-bearing soluble form
, interleukin receptor beta chain
, interleukin-6 receptor subunit beta
, membrane glycoprotein 130
, membrane glycoprotein gp130
, oncostatin-M receptor subunit alpha
, interleukin-6 signal transducer
, interleukin 6 signal transducer
, glycoprotein 130
, LOW QUALITY PROTEIN: interleukin-6 receptor subunit beta
, interleukin 6 signal transducer (gp130, oncostatin M receptor)
, interleukin 6 signal transducer receptor